Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 25;49(6):772-778.
doi: 10.3785/j.issn.1008-9292.2020.12.13.

[Tissue factors and venous thromboembolism in cancer patients]

[Article in Chinese]
Huiqi Zhu  1 , Kejing Ying  1
Affiliations

[Tissue factors and venous thromboembolism in cancer patients]

[Article in Chinese]
Huiqi Zhu et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. .

Abstract
in English, Chinese

Malignant tumor is one of the important acquired risk factors of venous thromboembolism (VTE). As the transmembrane receptor of coagulation factor Ⅶ and activated coagulation factor Ⅶa in vivo, tissue factor is the main initiator of exogenous coagulation. Tissue factor positive particles expressed and released by tumor cells enter the circulation and mediate thrombosis in patients with surgical treatment and distant tumor metastasis; the enhanced procoagulant activity of tissue factor after chemotherapy makes many cancer patients more likely to develop thromboembolic disease. Tissue factors can also be used to predict the risk of VTE in patients with pancreatic cancer, colorectal cancer and ovarian cancer.This article summarizes the role of tissue factor in VTE of cancer patients at different treatment stages, and further clarifies the relationship between tissue factor and the risk of VTE in cancer patients.

恶性肿瘤是静脉血栓栓塞（VTE）的重要获得性危险因素之一。组织因子作为体内凝血因子Ⅶ和活化形式的凝血因子Ⅶa的跨膜受体，是机体外源性凝血过程的主要起始物。肿瘤细胞表达释放的组织因子阳性微粒进入循环参与介导手术治疗和肿瘤远处转移患者的血栓形成；化疗后组织因子促凝活性增强导致很多肿瘤患者接受化疗后更容易发生血栓栓塞性疾病。在胰腺癌、结直肠癌和卵巢癌等肿瘤中，组织因子还可以用于预测患者VTE风险。本文总结了近年来组织因子在不同治疗阶段的肿瘤患者VTE中的作用，进一步明确组织因子与肿瘤患者VTE风险之间的关系。

Keywords: Neoplasm metastasis; Prediction; Review; Tissue factors; Tumor therapy; Venous thromboembolism.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. PABINGER I, THALER J, AY C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013;122(12):2011–2018. doi: 10.1182/blood-2013-04-460147. - DOI - PubMed
    1. TIMP J F, BRAEKKAN S K, VERSTEEG H H, et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712–1723. doi: 10.1182/blood-2013-04-460121. - DOI - PubMed
    1. FALANGA A, PANOVA-NOEVA M, RUSSO L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol. 2009;22(1):49–60. doi: 10.1016/j.beha.2008.12.009. - DOI - PubMed
    1. FALANGA A, MARCHETTI M, VIGNOLI A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost. 2013;11(2):223–233. doi: 10.1111/jth.12075. - DOI - PubMed
    1. EDWARDS R L, MORGAN D L, RICKLES F R. Animal tumor procoagulants: registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis. Thromb Haemost. 1990;63(1):133–138. doi: 10.1055/s-0038-1645699. - DOI - PubMed